(19) |
 |
|
(11) |
EP 4 512 402 A3 |
(12) |
EUROPEAN PATENT APPLICATION |
(88) |
Date of publication A3: |
|
30.04.2025 Bulletin 2025/18 |
(43) |
Date of publication A2: |
|
26.02.2025 Bulletin 2025/09 |
(22) |
Date of filing: 18.08.2022 |
|
(51) |
International Patent Classification (IPC):
|
|
(84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
(30) |
Priority: |
18.08.2021 US 202163234606 P
|
(62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
22785813.1 / 4367118 |
(71) |
Applicants: |
|
- Nurix Therapeutics, Inc.
San Francisco, CA 94158 (US)
- Gilead Sciences, Inc.
Foster City, CA 94404 (US)
|
|
(72) |
Inventors: |
|
- PALMER, Wylie
San Francisco, 94158 (US)
- WU, Jeffrey
San Francisco, 94158 (US)
- LEE, John
San Francisco, 94158 (US)
- OZBOYA, Kerem
San Francisco, 94158 (US)
- KANE, Tim
San Francisco, 94158 (US)
|
(74) |
Representative: Carpmaels & Ransford LLP |
|
One Southampton Row London WC1B 5HA London WC1B 5HA (GB) |
|
|
|
(54) |
BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC
USE THEREOF |
(57) The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin
proteasome pathway, and method for treating diseases modulated by IRAK4.